Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases Takuro Wada, O Sato, A Kawai, T Hasegawa Sapporo.

Slides:



Advertisements
Similar presentations
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Advertisements

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
Frequency of MDM2 Amplification in Malignant Peripheral Nerve Sheath Tumors: Non-Correlation with Tumor Grade, Cellularity and MIB1 Proliferation Index.
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in chondrosarcomas Makoto Endo, 1 Tadaki Matsumura, 2 Umio Yamaguchi, 1 Fumihiko.
Janet Eary 1, Janet O'Sullivan 3, Finbarr O'Sullivan 3, E. U. Conrad 2 1. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States.
Rarer Sarcoma Subtypes Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Boston, MA.
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.
Musculoskeletal Oncology Service, National Cancer Center Hospital Musculoskeletal Oncology Service, Keio University Hospital An Analysis of Clinicopathological.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
November 2006 Phase II Study of Dasatinib in Advanced Sarcoma SARC 009 Coordinating site: University of Michigan.
A detection system for circulating tumor cells using GFP expressing telomerase-specific replication-competent adenovirus in bone and soft tissue sarcoma.
CXCR4 receptor is correlated to the development of metastases in leiomyosarcoma, pleomorphic sarcoma and liposarcoma S.C.D.U. Medical Oncology I.R.C.C.
E2F3 in Soft Tissue Sarcoma Development M. Scurr; A Feber; J Shipley; A Fletcher; N Dennis; I Judson; C Cooper.
Clinical Outcomes and Patterns of Failure in Pineoblastoma: A 30-year Single Institution Experience Benjamin Farnia, B.A. ASTRO Poster Discussion September.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Kerrington Smith, M.D. CTOS Nov 14, 2008
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
LUNG ADENOCARCINOMAS. CLINICOPATHOLOGICAL STUDY WITH RESPECT TO THE UPCOMING NEW CLASSIFICATION AND EGFR-KRAS MUTATION ANALYSIS IMPLICATIONS. First author:
Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1,
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas Ryan M. Lanning, Sean L. Berry, Michael.
An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.
HCI Sarcoma Services Sequential Dependency of Radiotherapy for Soft-Tissue Sarcoma S Sampath TE Schultheiss YJ Hitchcock RL Randall DC Shrieve JYC Wong.
Conclusion IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION (ANATOLIAN.
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
ANNUAL SLIDE SEMINAR June Bratislava Slovakia B. Fredrik Petersson MD, PhD Department of Pathology, Karolinska University Hospital Stockholm.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
Sarcomas Perspectives and Background. Sarcomas: Themes Sarcomas are a heterogeneous collection of diseases and families of diseases –Individual diseases/families.
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Estimating the population-based incidence for sarcoma and GIST in three European regions G. Mastrangelo University of Padova.
Factors Influencing Sarcoma Referral and Treatment William G. Ward, Matthew T. Cline, Fred J. Dorey* Wake Forest University Health Sciences, Winston-Salem,
Chiba Cancer Center, Chiba, Japan Shintaro Iwata Tsukasa Yonemoto Yoko Hagiwara Takeshi Ishii Division of Orthopedic Surgery Akinobu Araki Dai Ikebe Division.
Prognostic value of myogenic differentiation in adult soft tissue sarcomas (STS) A study of 855 cases from the French Sarcoma Group N Stock, MC Chateau,
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Symposium 2: Sarcoma of the Year – Synovial Sarcoma Peter Reichardt HELIOS Klinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg.
Jens Jakob 1 ; Anna Simeonova 2 ; Bernd Kasper 3 ; Ulrich Ronellenfitsch 1 ; Frederik Wenz 2 ; Peter Hohenberger 1 1 Department of Surgery, 2 Department.
Phase II Study of Dasatinib (BMS ) in Advanced Sarcomas and Chordoma Coordinating Center: U Michigan.
1 Sarcoma Ages >= ** Analytic - Initially Diagnosed and/or received all or part of 1st course treatment at.
Malignancy Grade and Histologic Subtype of Primary Retroperitoneal Sarcoma (RPS) are Predictive of Pattern of Recurrence: a Large Retrospective Study from.
Cutaneous Carcinosarcoma Katy H. Goldsborough, William B. Laskin, Jeffrey D. Wayne, Mark Agulnik Department of Medicine, Division of Hematology/ Oncology,
Institut Bergonié 1 MULTICENTRIC EVALUATION OF THE FRENCH SURGICAL SYSTEM IN SOFT TISSUE SARCOMA (STS). E. Stoeckle, S. Bonvalot, JY Blay, L. Guillou,
FOCUS INTERGROUP COLLABORATION AGAINST SARCOMAS (ICAS) FOCUS Biologically targeted therapeuticsBiologically targeted therapeutics Histology specificHistology.
Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.
Local Recurrence Growth Rate Predicts Outcome In Locally Recurrent Retroperitoneal Liposarcoma James Park, MD, Li-Xuan Qin, PhD, Francesco Prete, MD Murray.
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Wilms’ tumour gene 1 (WT1) is a new prognostic marker in high grade uterine sarcoma A. Coosemans, B. Van Calster, L. Verbist, Ph. Moerman, I. Vergote,
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
: 1.Introduction The cold shock “Y-box binding protein-1” (YB-1) has an important role in regulation of cellular proliferation and differentiation. Overexpression.
University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.
Discussion & Conclusion Predictives of Meningioma Grading
Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.
Discordance of histo-pathological diagnosis of patients with soft tissue sarcoma referred to tertiary care center. Rastogi,S., Aggarwal, A., Soti, K.,
Prognosis of younger patients in non-small cell lung cancer
Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.
Published online September 20, 2017 by JAMA Surgery
PRIMARY EXTREMITY STS: MULTIMODAL APPROACH MAY HAVE IMPROVED SURVIVAL
HISTOLOGY-SPECIFIC NOMOGRAM FOR PATIENTS AFFECTED BY PRIMARY RSTS
Immunohistochemical determination of TIM-3 expression in ccRCC.
Presentation transcript:

Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases Takuro Wada, O Sato, A Kawai, T Hasegawa Sapporo Medial University, Sapporo Japan National Cancer Center, Tokyo Japan

Purpose To analyze expression patterns of EGFR, ERBB2, and KIT on 281 patients with common adult STS by standard immunohistochemical technique on formalin-fixed, paraffin-embedded sections To Verify whether a significant association with prognosis is present

Patients 281 adult patients with common soft tissue sarcomas in the extremities and trunk diagnosed and treated at the NCC, Tokyo, Japan Histologic subtype Fibrosarcoma (FS) 11 Leiomyosarcoma (LMS) 11 Myxoid liposarcoma ( LSM) 52 Well differentiated liposarcoma ( LSW) 50 MPNST 18 Myxofibrosarcoma (MFS) 53 Pleomorphic MFH (PMFH) 44 Synovial sarcoma (SS) 42

Exclusion Tumor histology (379 )  Rhabdomyosarcoma, Ewing sarcoma  ASPS, angiosarcoma, epithelioid sarcoma,….. Location (42)  Retroperitoneal, head and neck, visceral, intrathoracic Stage IV (43)

Characteristic of 281 patients Gender:152 females and 129 males Age:10 to 85 years (median 50 yrs) Treatment:  ResectionAll patients  Radiotherapy25  Chemotherapy37  Chemo + Radi23

Pathology reviewing, grade and Staging Tumor typing  WHO Classification of Soft Tissue Tumors Histologic grade  Differentiation, necrosis, MIB-1 index TNM staging classification

Primary Antibodies AntibodySourceDilutionPositive control EGFR, mouse monoclonal DakoCytomation, Clone 2-18C9 PredilutedBreast ca ERBB2, rabbit polyclonal DakoCytomation1:500Breast ca KIT, rabbit polyclonal DakoCytomation1:50Mast cell

0 1+ or ≤ 10% = Negative 2+ 3+ and >10% = Positive StrengthDistribution Evaluation of staining

Results

Immunohistochemical Pattern Histologic typeNo.EGFR Fibrosarcoma114 (36%) Leiomyosarcoma118 (73%) Myxoid liposarcoma523 (6%) Well-D liposarcoma5019 (38%) Myxofibrosarcoma5316 (89%) MPNST1847 (89%) PMFH4439 (89%) Synovial sarcoma4232 (76%) Total (60%)

Immunohistochemical Pattern Histologic typeNo.EGFRERBB2KIT Fibrosarcoma114 (36%)00 Leiomyosarcoma118 (73%)00 Myxoid liposarcoma523 (6%)00 Well-D liposarcoma5019 (38%)00 Myxofibrosarcoma5316 (89%)00 MPNST1847 (89%)00 PMFH4439 (89%)00 Synovial sarcoma4232 (76%)32 Total (60%)32

Diffuse EGFR (2+) in leiomyosarcoma Diffuse EGFR (3+) in MPNST

Diffuse EGFR (3+) in spindle cells of biphasic synovial sarcoma Focal ERBB2 (2+) in epithelioid cells of biphasic synovial sarcoma

Focal KIT (2+) in spindle cells of monophasic synovial sarcoma

EGFR (+) EGFR (-) 79 % 64 %

Variables associated with patient survival: Univariate analysis Stage Histological grade Depth Size Positive EGFR staining

Variables associated with patient survival: Multivariate analysis Stage Histological grade Depth Size Positive EGFR staining

Kaplan-Meier survival curves stratified by EGFR status and by tumor size Size 5-10cm (n=135) Size>10cm (n=77) EGFR- EGFR+ p=0.03 p=0.06

Kaplan-Meier survival curves stratified by EGFR status and by histological grade Grade 2 (n=74) Grade 3 (n=111) EGFR- EGFR+ p=0.08 p=0.7

Discussion

Expression of EGFR in STSs AuthorsCasesPositiveSubtype Gusterson et al. (1985)3518 (51%)MFH, SS, Epi Perosio et al. (1989)4020 (50%) Duda et al. (1993)4321(49%) Barbashina (2002)1913 (68%)SS Nielsen (2002)4218 (52%)SS This study (60%) MFH, SS, MPNST

Expression of ERBB2 and KIT Merimsky et al. (2002)  No overexpression of ERBB2 in 230 STSs Hornick et al. (2002)  Very limited expression of KIT in 365 STSs This study  Limited expression of ERBB2 and KIT

EGFR (+) EGFR (-) 79 % 64 %

IMC-C225 ABX-EGF Tyrosine kinase inhibitor Irresa Target-specific agents and approaches for anticancer therapy

Conclusion We analyzed the expression of EGFR, ERBB2, and KIT in 281 patients with STS Positive staining of EGFR: 168/281 (60%) Positive staining of ERBB2, KIT was limited EGFR overexpression was a negative prognostic factor associated with histological grade

Immunohistochemical Pattern

Use of Immunohistochemistry (IHC) to Detect EGFR Expression in Tumors Detects expression of EGFR protein on surface of tumor cells, with direct visualization of the target Reagents and equipment commonly available Widely used in many clinical studies Standardized methods are being developed

Risk of Invasion/ Tumor TypePrognosisSurvivalMetastasesReferences ColorectalPoorMayer (1993) Poor Increased Hemming (1992) Head and NeckDecreased DFSGrandis (1998) PoorDecreased OSMaurizi (1996) PancreaticPoorDong (1998) Decreased OSYamanaka (1993) NSCLCDecreased OSVolm (1998) Decreased OSVeale (1993) PoorDecreased OSOhsaki (2000) IncreasedPavelic (1993) Abbreviations: DFS, disease-free survival; OS, overall survival; NSCLC, non-small cell lung cancer. EGFR Expression Correlated With:

Summary EGFR overexpression was associated with poor prognosis in soft tissue sarcomas. Our study demonstrated frequent overexpression of EGFR in adult-type soft tissue sarcomas, and associated with histologic grade. We also confirmed very limited expression of KIT and HER2 in these tumors.

Target-specific agents and approaches for anticancer therapy